China National Biotec Group
http://www.cnbg.com.cn
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From China National Biotec Group
Asia Deal Watch: Astellas Seeks Pantherna’s Assistance On mRNA-Based Regenerative Medicine
Plus deals involving OliPass/Vanda, Simcere/Almirall, Sinopharm/Merck & Co., Jiuzhou/Sandoz, Zai Lab/Seagen, Sciwind/SynderK, Hansoh/KiOmed.
New Front-Runner Emerges In China mRNA Booster Race
China's CSPC Pharmaceutical Group surprises by announcing investigator-initiated trial results for SYS6006, its mRNA COVID-19 vaccine candidate against the Omicron variant.
Boosters Miss Growth Expectations Despite China COVID Surge
While two Chinese companies gained domestic approvals for their recombinant protein and adenovirus-based COVID-19 shots as heterologous boosters in February, these currently only account for roughly 21% of all booster shots, showing the continued predominance of inactivated virus-based technology in the country.
China OKs Heterologous Booster Shots Amid Heated COVID Vaccine Race
CanSino and Zhifei have received the regulatory green light for their respective COVID-19 booster shots in China and an estimated $1.3bn vaccine market is now up for grabs. Domestic contenders are set to elbow each other in the sector with a range of viral vector, recombinant protein and mRNA-based jabs.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice